Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €44.83 EUR
Change Today -0.335 / -0.74%
Volume 1.1K
6MK On Other Exchanges
New York
Sao Paulo
As of 12:22 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (6MK) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - €56.21
52 Week Low
10/16/14 - €41.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERCK & CO. INC. (6MK)

merck & co. inc. (6MK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. It has a strategic collaboration with Bionomics Limited. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

68,805 Employees
Last Reported Date: 08/6/15
Founded in 1891

merck & co. inc. (6MK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $3.2M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.5M
President of Global Human Health and Executiv...
Total Annual Compensation: $962.4K
Compensation as of Fiscal Year 2014.

merck & co. inc. (6MK) Key Developments

Bionomics Announces Extension of Strategic Collaboration with Merck

Bionomics Limited has extended its strategic collaboration with Merck & Co. Inc. for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain. Merck &Co. Inc. will make $9 million investment in Bionomics. The latest agreement builds upon a collaboration signed in July 2013 focused on the discovery and development of novel, small molecule drug candidates for the treatment of chronic and neuropathic pain utilizing Bionomics's ionX and MultiCore drug discovery platforms.

Merck Announces FDA Approval of KEYTRUDA® (pembrolizumab)

Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) monotherapy, the company’s anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. Under FDA’s accelerated approval regulations, this indication for KEYTRUDA is approved based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. KEYTRUDA is the first and only anti-PD-1 therapy approved for both squamous and non-squamous metastatic NSCLC. In addition to approving KEYTRUDA for NSCLC, FDA approved the first companion diagnostic that will enable physicians to determine the level of PD-L1 expression in a patient’s tumor. In KEYNOTE-001, the clinical study supporting the FDA Breakthrough Designation for KEYTRUDA and this approval, KEYTRUDA demonstrated an overall response rate of 41% (n=25/61) in patients with a PD-L1 expression tumor proportion score (TPS) of 50% or more; all responses were partial responses (95% CI, 29, 54). 84% (n=21/25) of those who responded had ongoing responses, including 11 patients with ongoing responses of six months or longer. Immune-mediated adverse reactions occurred with KEYTRUDA including pneumonitis, colitis, hepatitis, hypophysitis, hyperthyroidism, hypothyroidism, type 1 diabetes mellitus, and nephritis. Based on the severity of the adverse reaction, KEYTRUDA (pembrolizumab) should be withheld or discontinued and corticosteroids administered. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Female patients of reproductive potential should be advised of the potential hazard to a fetus.

Merck & Company Collaborates with DNAtrix to Study DNX-2401, Keytruda in Glioblastoma

Merck & Company has entered into a collaboration with DNAtrix for an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix's oncolytic immunotherapy in combination with Keytruda. The phase 2 study will be on patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6MK:GR €44.83 EUR -0.335

6MK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $147.73 USD +0.19
Amgen Inc $146.94 USD -1.11
Bayer AG €112.10 EUR -2.62
Gilead Sciences Inc $98.29 USD -1.98
L'Oreal SA €162.05 EUR +1.10
View Industry Companies

Industry Analysis


Industry Average

Valuation 6MK Industry Range
Price/Earnings 14.5x
Price/Sales 3.5x
Price/Book 3.0x
Price/Cash Flow 14.2x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at